AstraZeneca: Pulmonary Disease, Chronic Obstructive trials

The registry lists 284 Pulmonary Disease, Chronic Obstructive studies with AstraZeneca as lead sponsor. 14 are open to participants now and 127 have results posted.

Early Phase 1 2Phase 1 42Phase 2 57Phase 3 77Phase 4 19No phase 90(a study in two phases counts in both)

Studies

Page 1 of 3. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• BREZTRI REGULATORY POST MARKETING SURVEILLANCE IN KOREARecruitingNCT07570394
• Long-term Safety and Tolerability of Tozorakimab in Patients With COPD and History of ExacerbationsRecruitingNCT07566195Phase 3
• Study for Assessing the Prevalence of Airflow Limitation in Outpatients With History of Smoking Attending Cardiology ClinicsRecruitingNCT07315958
• Study of Patient With Frequent Exacerbations in MoscowRecruitingNCT07307781
• Assess Accuracy of Primary Care Asthma and COPD Diagnosis Using Oscillometry and FeNO vs Specialist DiagnosisRecruitingNCT07245576
• A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary DiseaseRecruitingNCT07082738Phase 2
• A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and HyperinflationRecruitingNCT07073950Phase 4
• Study of Clinical and Patient-reported Outcomes in Adults With Moderate to Severe COPD Treated With Breztri/TrixeoRecruitingNCT07069829
• A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)RecruitingNCT06883305Phase 3
• A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)RecruitingNCT06878261Phase 3
• Study That Will Evaluate the Brazilian Population With COPD.RecruitingNCT06780046
• A Translational Study for Prediction of Biomarkers and Identification of Phenotype and Endotype of COPD and Pre-COPD Outcomes in Chinese PopulationRecruitingNCT06724848
• Post-marketing Phase 4 Safety & Tolerability Study of Breztri aerosphereTM in Indian Patients With Chronic Obstructive Pulmonary DiseaseRecruitingNCT06531798Phase 4
• A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary DiseaseRecruitingNCT06283966Phase 3
• A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With a Next-Generation Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary DiseaseCompletedNCT05573464Phase 3Results posted
• A Study to Assess the Total Systemic Exposure Bioequivalence of of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA PropellantCompletedNCT05569421Phase 1Results posted
• An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD.CompletedNCT05492877Phase 2Results posted
• Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA PropellantCompletedNCT05477108Phase 1Results posted
• A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic BronchitisCompletedNCT04631016Phase 2Results posted
• A Study to Assess Drug Absorption of Fixed Dose Combinations of Budesonide, Glycopyrronium, and FormoterolCompletedNCT04600505Phase 1Results posted
• Study Comparing Dual Combination of Product (Budesonide and Formoterol) Given Via Two Different Inhalers. To See Which One Results in the Best Effect on Breathing.CompletedNCT04078126Phase 3Results posted
• Tezepelumab COPD Exacerbation StudyCompletedNCT04039113Phase 2Results posted
• A Study to Evaluate the Effects of BGF and GFF on Specific Image Based Airway Volumes and Resistance in Subjects With Moderate to Severe COPDCompletedNCT03836677Phase 3Results posted
• A Single Inhalation Dose Study to Assess Efficacy, Pharmacokinetics (PK), Safety and Tolerability of AZD8871 in Patients With Long-term Lung Diseases.CompletedNCT03645434Phase 2Results posted
• A Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD7594 Administered Once Daily by Inhalation in Asthmatic SubjectsCompletedNCT03622112Phase 2Results posted
• A Randomized, Open-label, Single-dose, Single-center, Crossover Study in Healthy Subjects to Assess the Relative Bioavailability of PT010CompletedNCT03311373Phase 1Results posted
• Pharmacokinetics, Safety and Tolerability of Twice-Daily Aclidinium Bromide/Formoterol Fumarate Fixed Dose Combination in Chinese Patients With Moderate to Severe Chronic Obstructive Pulmonary DiseaseCompletedNCT03276078Phase 2Results posted
• Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With COPD Compared With Symbicort® Turbohaler®CompletedNCT03262012Phase 3Results posted
• Study to Assess the Efficacy and Safety of Three Doses of PT001 in Japanese Subjects With Moderate to Severe COPDCompletedNCT03256552Phase 2Results posted
• A Study to Assess the PK and Safety of PT010 in Subjects With COPD Following Single and Repeat DoseCompletedNCT03250182Phase 1Results posted
• Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary DiseaseCompletedNCT03162055Phase 3Results posted
• Pharmacokinetics and Safety Study of PT010 and PT003 in Healthy Chinese Adult SubjectsCompletedNCT03075267Phase 1Results posted
• Study to Assess Efficacy and Safety of Aclidinium Bromide and Aclidinium Bromide/Formoterol Fumarate in Stabile COPD PatientsCompletedNCT03022097Phase 3Results posted
• Efficacy, Pharmacokinetics (PK), Safety and Tolerability Study of Inhaled AZD8871CompletedNCT02971293Phase 2Results posted
• Pharmacokinetic Comparability of Benralizumab Using Accessorized Pre-Filled Syringe or Autoinjector in Healthy VolunteersCompletedNCT02968914Phase 1Results posted
• A Study to Assess the Effects of PT001 and PT005 MDI on Specific Image Based Parameters in Subjects With Moderate to Severe COPDCompletedNCT02937584Phase 3Results posted
• Adherence Study in COPD PatientsCompletedNCT02864342Phase 4Results posted
• Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD8871 in Healthy SubjectsCompletedNCT02814656Phase 1Results posted
• AMPLIFY - D6571C00001 Duaklir USA Phase III StudyCompletedNCT02796677Phase 3Results posted
• Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)CompletedNCT02796651Phase 2Results posted
• Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPDCompletedNCT02766608Phase 3Results posted
• A Study to Assess the Efficacy and Safety of PT009 Compared to PT005 on COPD Exacerbations Over a 52-Week Period in Subjects With Moderate to Very Severe COPD (Sophos)CompletedNCT02727660Phase 3Results posted
• Study to Evaluate the Treatment Effect of PT003 on Cardiovascular Hemodynamics in Subjects With Moderate to Severe COPDTerminatedNCT02685293Phase 3Results posted
• A Study to Assess the Bioavailability and to Compare the Pharmacokinetics of AZD7594 Inhaled Via Monodose Inhaler and Multiple-dose Dry Powder Inhalers (DPI) or Pressurized Metered-dose Inhaler (pMDI) in Healthy Male SubjectsCompletedNCT02648438Phase 1Results posted
• A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7594 Inhaled Formulation in Healthy Japanese MenCompletedNCT02645253Phase 1Results posted
• A Study to Assess the Effects of PT003 and Placebo MDI on Specific Image Based Airway Volumes and Resistance in Subjects With Moderate to Severe COPDCompletedNCT02643082Phase 3Results posted
• Two-part Safety, Tolerability, Pharmacodynamic and -Kinetic Study of Inhaled AZD8871 in Asthmatic and COPD SubjectsCompletedNCT02573155Phase 1Results posted
• Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary DiseaseCompletedNCT02536508Phase 3Results posted
• Phase IV O2 Consumption Study in COPD Patients.CompletedNCT02533505Phase 4Results posted
• A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos)CompletedNCT02497001Phase 3Results posted
• Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)CompletedNCT02465567Phase 3Results posted
• Crossover Study to Assess the Efficacy of PT003 With and Without a Valved Holding Chamber in Subjects With Moderate to Severe COPDCompletedNCT02454959Phase 3Results posted
• Effect of Aclidinium/Formoterol on Lung Hyperinflation, Exercise Capacity and Physical Activity in Moderate to Severe COPD PatientsCompletedNCT02424344Phase 4Results posted
• BENEFITS OF ACLIDINIUM BROMIDE IN THE RELIEF OF COPD SYMPTOMS INCLUDING COUGHCompletedNCT02375724Phase 4Results posted
• 24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003 and Placebo MDICompletedNCT02347085Phase 3Results posted
• 24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003, Open-Label Spiriva® Respimat® as an Active Control, and PlaceboCompletedNCT02347072Phase 3Results posted
• Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPDCompletedNCT02343458Phase 3Results posted
• Glycopyrronium and Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) Dose Indicator Study in Adults With Moderate to Very Severe COPDCompletedNCT02268396Phase 3Results posted
• A Phase IIa Study to Investigate the Efficacy and Safety of AZD7624 in Chronic Obstructive Pulmonary Disease (COPD) Patients While on Maintenance TherapyCompletedNCT02238483Phase 2Results posted
• PK Study of PT003 and PT001 in Japanese Healthy SubjectsCompletedNCT02196714Phase 1Results posted
• Efficacy and Safety Study of PT009, PT008, and PT005 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02196077Phase 2Results posted
• Evaluation of Tolerability and Pharmacokinetics of Roflumilast, 250μg and 500μg, as add-on to Standard COPD Treatment to Treat Severe COPDCompletedNCT02165826Phase 3Results posted
• Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary DiseaseCompletedNCT02157935Phase 3Results posted
• Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation HistoryCompletedNCT02155660Phase 3Results posted
• A Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of Aclidinium Bromide 400 μg Bid on COPD Symptoms and Sleep Quality After 3 Weeks of Treatment in Patients With Stable Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02153489Phase 4Results posted
• Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation HistoryCompletedNCT02138916Phase 3Results posted
• Two-part Pharmacokinetic and Pharmacodynamic Study of LAS190792 in Patients With Asthma and COPDCompletedNCT02059434Phase 1Results posted
• Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)CompletedNCT01970878Phase 3Results posted
• Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.CompletedNCT01966107Phase 4Results posted
• Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01908140Phase 3Results posted
• Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)CompletedNCT01854658Phase 3Results posted
• Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)CompletedNCT01854645Phase 3Results posted
• To Assess the Safety, Tolerability, and Pharmacokinetics of AZD7624 in Healthy Volunteers and COPD PatientsCompletedNCT01817855Phase 1Results posted
• A Single-dose Study to Investigate the Effects of 4 Different Doses of Inhaled AZD8683 in Chronic Obstructive Pulmonary Disease (COPD) PatientsTerminatedNCT01708057Phase 2Results posted
• Glycopyrrolate/Formoterol Fumarate MDI Compared With Spiriva® as An Active Control in Patients With Moderate to Severe Chronic Obstructive Pulmonary DiseaseCompletedNCT01587079Phase 2Results posted
• Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01572792Phase 3Results posted
• PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPDCompletedNCT01566773Phase 2Results posted
• Pharmacokinetic, Safety and Tolerability Study of Aclidinium/Formoterol Fixed Dose Combination and Formoterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01551888Phase 2Results posted
• Trial to Assess the Anti-inflammatory Effects of Roflumilast in Chronic Obstructive Pulmonary DiseaseCompletedNCT01509677Phase 3Results posted
• Effect of Roflumilast at Acute Exacerbations of Chronic Obstructive Pulmonary DiseaseTerminatedNCT01473758Phase 2Results posted
• Efficacy and Safety of Aclidinium Bromide 400 µg BID (Twice a Day)Compared to Placebo in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01471171Phase 3Results posted
• Long-term Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate Fixed-Dose CombinationCompletedNCT01462942Phase 3Results posted
• Efficacy and Safety of Aclidinium Bromide 400 µg Compared to Placebo and to Tiotropium Bromide in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01462929Phase 3Results posted
• A Study to Evaluate the Efficacy of MEDI8968 in Chronic Obstructive Pulmonary DiseaseCompletedNCT01448850Phase 2Results posted
• Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)CompletedNCT01443845Phase 4Results posted
• Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary DiseaseCompletedNCT01437540Phase 3Results posted
• Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01437397Phase 3Results posted
• Single Dose Study to Assess Efficacy and Safety of 4 Doses of LAS100977 in Chronic Obstructive Pulmonary Disease (COPD) PopulationCompletedNCT01425814Phase 2Results posted
• Single Dose Study to Assess Efficacy, Safety and Tolerability of LAS100977 in Asthmatic Patients.CompletedNCT01425801Phase 2Results posted
• Efficacy and Tolerability Study in Severe Chronic Obstructive Pulmonary Disease (COPD) PatientsCompletedNCT01415518Phase 4Results posted
• Efficacy and Tolerability of Symbicort as an add-on Treatment to Spiriva Compare With Spiriva Alone in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01397890Phase 4Results posted
• PT001 MDI Versus Atrovent Study in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01350128Phase 2Results posted
• PT003 MDI Dose Confirmation StudyCompletedNCT01349816Phase 2Results posted
• PT003 MDI Cardiovascular Safety StudyCompletedNCT01349803Phase 2Results posted
• Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Combinations of Long-acting β2-agonists (LABA) and Inhaled Glucocorticosteroid (ICS)CompletedNCT01329029Phase 4Results posted
• A Study to Evaluate the Safety of MEDI2338 in Subjects With Chronic Obstructive Pulmonary DiseaseCompletedNCT01322594Phase 1Results posted
• A Chronic Obstructive Pulmonary Disease (COPD) Trial Investigating Roflumilast on Safety and Effectiveness in China, Hong Kong and Singapore:CompletedNCT01313494Phase 3Results posted
• A 4 Week Study to Investigate the Safety and Tolerability of AZD5069 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01233232Phase 2Results posted
• A Study to Evaluate the Effectiveness of MEDI-563 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01227278Phase 2Results posted
• AZD2423 Safety and Tolerability Study in Patients With Moderate and Severe Chronic Obstructive Pulmonary Disease(COPD)CompletedNCT01215279Phase 2Results posted